» Articles » PMID: 33244084

Empty Mesoporous Silica Particles Significantly Delay Disease Progression and Extend Survival in a Mouse Model of ALS

Overview
Journal Sci Rep
Specialty Science
Date 2020 Nov 27
PMID 33244084
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Amyotrophic lateral sclerosis (ALS) is a devastating incurable neurological disorder characterized by motor neuron (MN) death and muscle dysfunction leading to mean survival time after diagnosis of only 2-5 years. A potential ALS treatment is to delay the loss of MNs and disease progression by the delivery of trophic factors. Previously, we demonstrated that implanted mesoporous silica nanoparticles (MSPs) loaded with trophic factor peptide mimetics support survival and induce differentiation of co-implanted embryonic stem cell (ESC)-derived MNs. Here, we investigate whether MSP loaded with peptide mimetics of ciliary neurotrophic factor (Cintrofin), glial-derived neurotrophic factor (Gliafin), and vascular endothelial growth factor (Vefin1) injected into the cervical spinal cord of mutant SOD1 mice affect disease progression and extend survival. We also transplanted boundary cap neural crest stem cells (bNCSCs) which have been shown previously to have a positive effect on MN survival in vitro and in vivo. We show that mimetic-loaded MSPs and bNCSCs significantly delay disease progression and increase survival of mutant SOD1 mice, and also that empty particles significantly improve the condition of ALS mice. Our results suggest that intraspinal delivery of MSPs is a potential therapeutic approach for the treatment of ALS.

Citing Articles

Recent advances in nanotherapeutics for HIV-associated neurocognitive disorders and substance use disorders.

Lomas C, Dubey R, Perez-Alvarez G, Lopez Hernandez Y, Atmar A, Arias A Nanomedicine (Lond). 2025; 20(6):603-619.

PMID: 39963928 PMC: 11902879. DOI: 10.1080/17435889.2025.2461984.


Recent Advancements in Nanomaterials: A Promising Way to Manage Neurodegenerative Disorders.

Nguyen T, Nguyen-Thi P, Nguyen T, Ho T, Tran N, Vo T Mol Diagn Ther. 2023; 27(4):457-473.

PMID: 37217723 DOI: 10.1007/s40291-023-00654-1.


Nanoparticle-Based Drug Delivery Systems: An Inspiring Therapeutic Strategy for Neurodegenerative Diseases.

Duan L, Li X, Ji R, Hao Z, Kong M, Wen X Polymers (Basel). 2023; 15(9).

PMID: 37177342 PMC: 10181407. DOI: 10.3390/polym15092196.


Design of Mesoporous Silica Nanoparticles for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with a Therapeutic Cocktail Based on Leptin and Pioglitazone.

Diaz-Garcia D, Ferrer-Donato A, Mendez-Arriaga J, Cabrera-Pinto M, Diaz-Sanchez M, Prashar S ACS Biomater Sci Eng. 2022; 8(11):4838-4849.

PMID: 36240025 PMC: 9667463. DOI: 10.1021/acsbiomaterials.2c00865.


Towards 3D Bioprinted Spinal Cord Organoids.

Han Y, King M, Tikhomirov E, Barasa P, Souza C, Lindh J Int J Mol Sci. 2022; 23(10).

PMID: 35628601 PMC: 9144715. DOI: 10.3390/ijms23105788.

References
1.
Zheng C, Nennesmo I, Fadeel B, Henter J . Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Ann Neurol. 2004; 56(4):564-7. DOI: 10.1002/ana.20223. View

2.
Aggarwal T, Hoeber J, Ivert P, Vasylovska S, Kozlova E . Boundary Cap Neural Crest Stem Cells Promote Survival of Mutant SOD1 Motor Neurons. Neurotherapeutics. 2017; 14(3):773-783. PMC: 5509618. DOI: 10.1007/s13311-016-0505-8. View

3.
Beers D, Appel S . Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019; 18(2):211-220. DOI: 10.1016/S1474-4422(18)30394-6. View

4.
Hjerling-Leffler J, Marmigere F, Heglind M, Cederberg A, Koltzenburg M, Enerback S . The boundary cap: a source of neural crest stem cells that generate multiple sensory neuron subtypes. Development. 2005; 132(11):2623-32. DOI: 10.1242/dev.01852. View

5.
Ogawa M . Mesoporous Silica Layer: Preparation and Opportunity. Chem Rec. 2016; 17(2):217-232. DOI: 10.1002/tcr.201600068. View